155 related articles for article (PubMed ID: 27576197)
1. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
Zhang Z; Duan Q; Zhao H; Liu T; Wu H; Shen Q; Wang C; Yin T
Cancer Lett; 2016 Nov; 382(1):53-63. PubMed ID: 27576197
[TBL] [Abstract][Full Text] [Related]
2. Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion
Li K; Zhang Z; Mei Y; Yang Q; Qiao S; Ni C; Yao Y; Li X; Li M; Wei D; Fu W; Guo X; Huang X; Yang H
Theranostics; 2021; 11(7):3196-3212. PubMed ID: 33537082
[TBL] [Abstract][Full Text] [Related]
3. Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.
Holcomb BK; Yip-Schneider MT; Waters JA; Beane JD; Crooks PA; Schmidt CM
J Gastrointest Surg; 2012 Jul; 16(7):1333-40. PubMed ID: 22618517
[TBL] [Abstract][Full Text] [Related]
4. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
Pan Y; Li K; Tao X; Zhao Y; Chen Q; Li N; Liu J; Go VLW; Guo J; Gao G; Xiao GG
Pancreas; 2021 Oct; 50(9):1260-1266. PubMed ID: 34860809
[TBL] [Abstract][Full Text] [Related]
6. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol.
Zhou L; Qi L; Jiang L; Zhou P; Ma J; Xu X; Li P
AAPS J; 2014 Mar; 16(2):246-57. PubMed ID: 24424498
[TBL] [Abstract][Full Text] [Related]
8. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
Ganguly K; Bhatia R; Rauth S; Kisling A; Atri P; Thompson C; Vengoji R; Ram Krishn S; Shinde D; Thomas V; Kaur S; Mallya K; Cox JL; Kumar S; Batra SK
Gastroenterology; 2022 Jan; 162(1):253-268.e13. PubMed ID: 34534538
[TBL] [Abstract][Full Text] [Related]
9. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Solca F; Modjtahedi H
Int J Oncol; 2016 Mar; 48(3):908-18. PubMed ID: 26781210
[TBL] [Abstract][Full Text] [Related]
11. The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC.
Lee YS; Kim HS; Kim HJ; Kang HW; Lee DE; Kim MJ; Hong WC; Kim JH; Kim M; Cheong JH; Park JS
J Mol Med (Berl); 2023 Nov; 101(11):1449-1464. PubMed ID: 37737908
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models.
Rabia E; Garambois V; Hubert J; Bruciamacchie M; Pirot N; Delpech H; Broyon M; Theillet C; Colombo PE; Vie N; Tosi D; Gongora C; Khellaf L; Jarlier M; Radosevic-Robin N; Chardès T; Pèlegrin A; Larbouret C
MAbs; 2021; 13(1):1914883. PubMed ID: 33876707
[TBL] [Abstract][Full Text] [Related]
13. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Knoop RF; Sparn M; Waldmann J; Plassmeier L; Bartsch DK; Lauth M; Hudemann C; Fendrich V
Neoplasia; 2014 Jun; 16(6):463-70. PubMed ID: 24953430
[TBL] [Abstract][Full Text] [Related]
14. Polyphenols from marine brown algae target radiotherapy-coordinated EMT and stemness-maintenance in residual pancreatic cancer.
Aravindan S; Ramraj SK; Somasundaram ST; Herman TS; Aravindan N
Stem Cell Res Ther; 2015 Sep; 6(1):182. PubMed ID: 26395574
[TBL] [Abstract][Full Text] [Related]
15. Huaier enhances the tumor-killing effect and reverses gemcitabine-induced stemness by suppressing FoxM1.
Wang Q; Gong M; Liu R; Mo J; Bai R; An R; Wang X; Han L; Wang Z; Ma Q; Wu Z; Zhou C
Phytomedicine; 2024 Jul; 129():155656. PubMed ID: 38723529
[TBL] [Abstract][Full Text] [Related]
16. Heat shock protein 47 confers chemoresistance on pancreatic cancer cells by interacting with calreticulin and IRE1α.
Yoneda A; Minomi K; Tamura Y
Cancer Sci; 2021 Jul; 112(7):2803-2820. PubMed ID: 34109710
[TBL] [Abstract][Full Text] [Related]
17. Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225.
Sclabas GM; Fujioka S; Schmidt C; Fan Z; Evans DB; Chiao PJ
J Gastrointest Surg; 2003 Jan; 7(1):37-43; discussion 43. PubMed ID: 12559183
[TBL] [Abstract][Full Text] [Related]
18. Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells.
Li D; Mullinax JE; Aiken T; Xin H; Wiegand G; Anderson A; Thorgeirsson S; Avital I; Rudloff U
BMC Cancer; 2018 Jul; 18(1):772. PubMed ID: 30064387
[TBL] [Abstract][Full Text] [Related]
19. Activin and Hepatocyte Growth Factor Promotes Colorectal Cancer Stemness and Metastasis through FOXM1/SOX2/CXCR4 Signaling.
Peng H; Ye T; Deng L; Yang X; Li Q; Tong J; Guo J
Gut Liver; 2024 May; 18(3):476-488. PubMed ID: 37458065
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells.
Han NK; Shin DH; Kim JS; Weon KY; Jang CY; Kim JS
Int J Nanomedicine; 2016; 11():1413-25. PubMed ID: 27103799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]